MedTrace Logo

Effects of E2, P4 and LH Levels on the Day of Transfer and Endometrial Cavity Thickness on Implantation Success in Patients With Frozen-thawed Embryo Transfer Cycle

NCT04769401 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 238

Last updated 2022-02-01

No results posted yet for this study

Summary

Thanks to recent advances in clinical practice and laboratory, embryo cryopreservation has become the first-line procedure in assisted reproductive technology. Embryo freezing process; Prevention of ovarian hyperstimulation syndrome is becoming an accepted practice for a growing number of indications, including preimplantation genetic testing (PGT), late follicular phase progesterone elevation, and embryo-endometrial asynchrony. Progesterone; plays a key role in the preparation of the endometrial cavity for embryo attachment. Supplementary progesterone preparations can be used to prevent luteal phase defects and provide progesterone support during cycle preparations for frozen-thawed embryo transfer. Our aim in this study is to show the effect of serum progesterone level on pregnancy outcomes on the day of embryo transfer.

Conditions

Interventions

OTHER

Normal Progesterone group

Progesteron supplementation was initiated by the use of 100 mg of a vaginal progesterone tablet two times daily (Lutinus, Ferring Pharmaceuticals) plus 250 mg of intramuscular hydroxyprogesterone caproate in oil twice a week (IMHPC) as luteal phase support (referred to as day 0 of progesterone administration).

OTHER

Low Progesterone group

Progesterone level \<10 ng/mL on ET day. If serum progesterone levels were \<10 ng/ml at ET day, 25 mg/d of SC progesterone daily (Prolutex) was given to patients and ET was performed on the same day and the blood sample was taken 2 days later to check serum progesterone levels.

Sponsors & Collaborators

  • Bezmialem Vakif University

    lead OTHER

Principal Investigators

  • pınar özcan · Bezmialem Foundation University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
41 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2021-11-21
Completion
2021-11-21

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04769401 on ClinicalTrials.gov